Prospective Prostate Cancer and Patient-reported Outcomes Registry
This study aims to evaluate the use of a digital solution, integrated into the electronic health record, for prospective and structured reporting of clinical and patient-reported outcomes for patients diagnosed with localized or locally advanced prostate cancer.
Prostate Cancer|Adenocarcinoma of the Prostate|Locally Advanced Prostate Carcinoma|Locally Advanced Prostate Adenocarcinoma
OTHER: standard of care
Assessment of systematically reporting a standardized set of predefined clinical parameters, The proportion of patients who are enrolled in the registry over the total localized and locally advanced prostate cancer patients, up to 10 years after diagnosis|Assessment of systematically collecting a predefined set of patient-reported outcomes, The proportion of patients who completed all questionnaires over the total of questionnaires send., up to 10 years after diagnosis
Occurence of disease recurrence/progression, Biochemical prostate specific antigen (PSA) recurrence/progression and recurrence/progression based on medical imaging, up to 10 years after diagnosis|General quality of life, Assessment of health-related quality of life in prostate cancer patients. Measured by EORTC Quality of Life Questionnaire C30 (QLQ-C30). The EORTC QLQ-C30 is a generic QoL questionnaire designed to cover issues important to all cancer patients, at diagnosis, 6 months, 1 year, and annually up to 10 years after diagnosis|Prostate cancer specific quality of life, Measured by Extended Prostate cancer Index Composite 26 (EPIC26). EPIC-26 is a validated instrument that measures the quality of life across 5 disease-specific domains: urinary incontinence, urinary obstruction and irritation, bowel-related symptoms, sexual dysfunction, and hormonal symptoms., at diagnosis, 6 months, 1 year, and annually up to 10 years after diagnosis|Overall Survival (OS), Overall survival is defined as the time from enrollment to date of death due to any cause., up to 10 years after diagnosis|Prostate Cancer (PC)-related Mortality (PM), PC-related mortality is the death due to prostate cancer., up to 10 years after diagnosis
This study aims to evaluate the use of a digital solution, integrated into the electronic health record, for prospective and structured reporting of clinical and patient-reported outcomes for patients diagnosed with localized or locally advanced prostate cancer.